Mr Stuart Dignam announced as new CEO of MTPConnect

Banner Image

26 April 2022

MTPConnect, the industry growth centre for the Medical Technology, Biotechnology and Pharmaceutical (MTP) sector, has appointed Mr Stuart Dignam as Chief Executive Officer.

Mr Dignam, formerly Chief Operating Officer, has been serving in the role of Interim CEO since 31 January 2022.

Mr Dignam joined MTPConnect in August 2018 and has played an integral role in building the organisation and helping design and develop its funding programs and new initiatives.

Prior to joining MTPConnect, Mr Dignam held senior roles at CPA Australia and with the Queensland Government, including as Deputy Trade and Investment Commissioner for the Americas. He has also worked as a broadcaster for ABC Radio and as a government media and policy advisor.

MTPConnect Chair, Sue MacLeman, said the appointment of Mr Dignam supports continuity and the expansion of activities currently underway, and reinforces the organisation’s strategic direction.

“The Board is delighted to welcome Mr Dignam to lead MTPConnect’s next chapter as it continues to make a significant contribution to supporting innovation and growth in the medical technology, biotechnology and pharmaceuticals sector,” Ms MacLeman said.

“With $180 million in project funds under management, new programs in South Australia and Western Australia and new projects dealing with health biosecurity, diagnostic testing and workforce skills, our role in supporting the medical products sector has never been more important.

“Mr Dignam brings a wealth of experience in developing successful programs and his background and knowledge make him the right person to lead deployment of our suite of new initiatives,” she said. 

Mr Dignam said he is looking forward to leading the MTPConnect team and working closely with sector stakeholders. 

“I am committed to making a difference to the MTP sector in Australia which is such an important driver of jobs and economic growth,” Mr Dignam said.

“Since establishment in 2015, we have contributed to nearly $1 billion flowing into Australia’s medical products sector and with new staff coming on board and significant new projects to deploy, our team is focused on maintaining that track record of success.”